U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure
17 avr. 2024 08h00 HE
|
Kaléo
Richmond, Virginia, April 17, 2024 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development...
Kaléo Expands Executive Team to Support Growth
27 juin 2023 08h00 HE
|
Kaléo
Richmond, VA, June 27, 2023 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to creating innovative healthcare solutions to protect and empower patients, today...
Kaléo Expands Executive Team to Support Growth
27 juin 2023 08h00 HE
|
Kaléo
Richmond, VA, June 27, 2023 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to creating innovative healthcare solutions to protect and empower patients, today...
Kaléo Adds Chief Business Officer to Executive Team
27 sept. 2022 08h00 HE
|
Kaléo
Richmond, VA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today...
Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids
21 sept. 2022 08h00 HE
|
Kaléo
Richmond, VA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kaléo, a privately held commercial-stage U.S. pharmaceutical company, today announced the execution of the first contract with the U.S. Department of...
Kaléo Announces Executive Appointments and New Government Business Unit
11 août 2022 08h25 HE
|
Kaléo
Richmond, VA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products for certain...